Please note: The information displayed on this page might be outdated.
Xylonix: Xylonix (Xylonix Pte. Ltd.) is an immuno-oncology biotech that is developing a new way of combating cancer through PARP1 DNA-repair overdrive for toxicity-free, widely applicable and curative first-in-class cancer immunotherapy drugs. Dubbed as onco-parthanatos agents, Xylonix’ lead development candidates, C005D and C008D, are being developed for future indicated use as monotherapy or in combination with other leading immunotherapies such as immune checkpoint inhibitors or CSF1R inhibitors.
Biotech Company / Healthcare/Biotechnology
Company Participants at Summer 2020 NYC Private Company Showcase
- Jinhyuk Fred Chung, PhD, CSO and President
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Summer 2020 NYC Private Company Showcase
New York, NY, August 10, 2020